Concepedia

Author

Victoria L. Peek

Eli Lilly (United States)

Also Known As

V.L. Peek, Victoria L Peek, Victoria L. Peek, Victoria Peek

52

Publications

647

Citations

8

H-Index

13

Concepts

All Affiliations

Eli Lilly (United States)
VL

About

Victoria L. Peek is an author at Eli Lilly (United States) specializing in cancer therapeutics, pharmacotherapy, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

41

2

Medicine

1

1

41

3

Cell Biology

1

1

41

4

Pharmacology

1

1

41

5

Cancer Therapeutics

1

1

41

Victoria L. Peek

×

8

Publications

606

Citations

8

H-Index

YearCitations

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie,

Investigational New Drugs

2012

159

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Sheng-Bin Peng, Victoria L. Peek, Yan Zhai,

Molecular Cancer Research

2005

107

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ling Liu, Wei Zeng, Mark A. Wortinger,

Clinical Cancer Research

2014

105

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Wenjuan Wu, Bi Chen, Kelly M. Credille,

Clinical Cancer Research

2013

67

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Bruce W. Konicek, Andrew Capen, Kelly M. Credille,

Oncotarget

2018

49

Human Splicing Factor SPF45 (<i>RBM17</i>) Confers Broad Multidrug Resistance to Anticancer Drugs When Overexpressed— a Phenotype Partially Reversed By Selective Estrogen Receptor Modulators

William L. Perry, Robert L. Shepard, Janardhan Sampath,

Cancer Research

2005

41

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Ravi Salgia, R Weaver, Michael McCleod,

Investigational New Drugs

2017

41

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

S. Betty Yan, Suzane L. Um, Victoria L. Peek,

Investigational New Drugs

2017

37

Page 1